GLP‑1 treatment in District of Columbia
Who ships GLP-1 medication to District of Columbia, what Medicaid covers, and the telehealth rules that apply.
What the federal data shows for District of Columbia
822 clinicians in District of Columbia prescribed Ozempic to Medicare Part D patients in 2024, across 16,052 claims. That is the most-prescribed GLP-1 in the state by prescriber count. Part D covers Medicare only, so the figure is a floor on prescribing in District of Columbia rather than a total.
District of Columbia Medicaid reimbursed $7,089,174.53 for 7,149 GLP-1 prescriptions in Q1 2026, or $991.63 per prescription. From CMS State Drug Utilization, fee-for-service and managed care combined. Suppressed cells are excluded, never counted as zero.
No outsourcing facility registered under section 503B gives a District of Columbia address in the FDA register. A compounded prescription filled for a District of Columbia patient is dispensed from a facility registered elsewhere.
What is on this page
- 6 drug cost pages for District of Columbia, each pairing the state's Medicaid figures with pharmacy acquisition cost
- 1 city pages showing where GLP-1 prescribers practise in District of Columbia
- Every link below is a page for District of Columbia specifically, not a national page filtered to it
- CMS NADACNational Average Drug Acquisition Cost, weekly file
- CMS Medicare Part DPrescriber public use file, by geography and drug
- CMS State Drug UtilizationQuarterly Medicaid prescription and reimbursement data
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.